Activated platelets with filopodia
Credit: John Weisel, PhD, Perelman School of Medicine, University of Pennsylvania
PHILADELPHIA -- The first view of the physical mechanism of how a blood clot contracts at the level of individual platelets is giving researchers from the Perelman School of Medicine at the University of Pennsylvania
a new look at a natural process that is part of blood clotting. A team led by John W. Weisel, PhD
, a professor of Cell and Developmental Biology, describes in Nature Communications
how specialized proteins in platelets cause clots to shrink in size.
To learn how a clot contracts, the Penn team imaged clots (networks of fibrin fibers and blood platelets) using an imaging technique called confocal light microscopy. The natural process of clot contraction is necessary for the body to effectively stem bleeding, reduce the size of otherwise obstructive clots, and promote wound healing.
The physical mechanism of platelet-driven clot contraction they observed is already informing new ways to think about diagnosing and treating conditions such as ischemic stroke, deep vein thrombosis, and heart attacks. In all of these conditions, clots are located where they should not be and block blood flow to critical parts of the body. Evidence from a study published earlier this year from the Weisel lab suggests that platelets in people with these diseases are less effective at clot contraction, thereby contributing to clots being more obstructive.
“Under normal circumstances, blood clot contraction plays an important role in preventing bleeding by making a better seal, since the cells become tightly packed as the spaces between them are eliminated,” Weisel said. “In this study, we unwrapped and quantified clot contraction in single platelets.” The team quantified the structural details of how contracting platelets cause clots to shrink, accompanied by dramatic structural alterations of the platelet-fibrin meshwork.
Contraction in the microcosm of a clot entails successive steps by platelet extensions called filopodia attaching to fibrin fibers and pulling on them. “We found that activated platelets bend and shorten individual fibrin fibers with their filopodia, which undergo sequential extension and retraction, as if pulling hand-over-hand on a rope,” Weisel said.
The same basic proteins used by platelets are also used in movements in muscle and other cells. In contrast to other cell-movement systems in which cells migrate along fibers or reorganize the extracellular matrix, the “hand-over-hand” pulling causes the shortening and bending of platelet-attached fibers. The mechanism of blood clot contraction the investigators observed represents a new mode of contractility by cells to reshape biological tissue.
With a better understanding of clot contraction, Weisel and coauthors think that its contributions to both prevention of bleeding and thrombosis can be studied more effectively. They surmise that methods to measure clot contraction could be used for diagnosis of its effects on bleeding or thrombosis, and perhaps in the future these effects might even be modulated with therapeutic interventions.
The research was funded by the National Institutes of Health (U01HL116330, HL090774), a Scientist Development Grant from American Heart Association (17SDG33680177), the Walter Cancer Foundation, the Program for Competitive Growth at Kazan Federal University, and the National Science Foundation (DMR 1505662).
Coauthors are Oleg V. Kim and Rustem I. Litvinov, both from Penn, and Mark S. Alber, University of Notre Dame.
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $7.8 billion enterprise.
The Perelman School of Medicine has been ranked among the top medical schools in the United States for more than 20 years, according to U.S. News & World Report’s survey of research-oriented medical schools. The School is consistently among the nation’s top recipients of funding from the National Institutes of Health, with $405 million awarded in the 2017 fiscal year.
The University of Pennsylvania Health System’s patient care facilities include: The Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center — which are recognized as one of the nation’s top “Honor Roll” hospitals by U.S. News & World Report — Chester County Hospital; Lancaster General Health; Penn Medicine Princeton Health; Penn Wissahickon Hospice; and Pennsylvania Hospital – the nation’s first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine, and Princeton House Behavioral Health, a leading provider of highly skilled and compassionate behavioral healthcare.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2017, Penn Medicine provided $500 million to benefit our community.